CERCA
MCID: CRV035
MIFTS: 73

Cervical Cancer (CERCA)

Categories: Cancer diseases, Genetic diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Cervical Cancer

MalaCards integrated aliases for Cervical Cancer:

Name: Cervical Cancer 57 11 75 73 53 41 2 14 63 71
Neoplasm of Uterine Cervix 11 28 5
Cervical Cancer, Somatic 57 12 5
Uterine Cervical Neoplasm 11 71
Cervix Cancer 11 73
Uterine Cervical Neoplasms 43
Tumor of the Cervix Uteri 11
Cancer, Cervical, Somatic 38
Malignant Tumor of Cervix 71
Uterine Cervical Cancer 73
Cervix Uteri Cancer 11
Neoplasms Cervical 53
Cervical Neoplasm 11
Cervix Carcinoma 71
Cervical Cancers 14
Cerca 73

Classifications:



External Ids:

Disease Ontology 11 DOID:4362
OMIM® 57 603956
ICD9CM 34 180
MeSH 43 D002583
NCIt 49 C2940 C9311
SNOMED-CT 68 123841004 254885005
ICD10 31 C53
SNOMED-CT via HPO 69 108369006 363346000
UMLS 71 C0007847 C0007873 C0302592 more

Summaries for Cervical Cancer

MedlinePlus: 41 The cervix is the lower part of the uterus, the place where a baby grows during pregnancy. Cervical cancer is caused by a virus called HPV. The virus spreads through sexual contact. Most women's bodies are able to fight HPV infection. But sometimes the virus leads to cancer. You're at higher risk if you smoke, have had many children, use birth control pills for a long time, or have HIV infection. Cervical cancer may not cause any symptoms at first. Later, you may have pelvic pain or bleeding from the vagina. It usually takes several years for normal cells in the cervix to turn into cancer cells. Your health care provider can find abnormal cells by doing a Pap test to examine cells from the cervix. You may also have an HPV test. If your results are abnormal, you may need a biopsy or other tests. By getting regular screenings, you can find and treat any problems before they turn into cancer. Treatment may include surgery, radiation therapy, chemotherapy, or a combination. The choice of treatment depends on the size of the tumor, whether the cancer has spread and whether you would like to become pregnant someday. Vaccines can protect against several types of HPV, including some that can cause cancer. NIH: National Cancer Institute

MalaCards based summary: Cervical Cancer, also known as neoplasm of uterine cervix, is related to cervix carcinoma and human papillomavirus infectious disease, and has symptoms including pelvic pain An important gene associated with Cervical Cancer is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are Breast cancer pathway and Interleukin-4 and Interleukin-13 signaling. The drugs Nicotine and Meperidine have been mentioned in the context of this disorder. Affiliated tissues include cervix, uterus and lymph node, and related phenotypes are neoplasm and abnormality of the cervical spine

CDC: 2 Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. When cancer starts in the cervix, it is called cervical cancer. The cervix connects the vagina (birth canal) to the upper part of the uterus. The uterus (or womb) is where a baby grows when a woman is pregnant. All women are at risk for cervical cancer. It occurs most often in women over age 30. Human papillomavirus (HPV) is the main cause of cervical cancer. HPV is a common virus that is passed from one person to another during sex. At least half of sexually active people will have HPV at some point in their lives, but few women will get cervical cancer. Cervical cancer is highly preventable in most Western countries because screening tests and a vaccine to prevent HPV infections are available. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.

PubMed Health : 63 Cervical cancer: Cervical cancer is the term used to describe tumors that can grow at the lower end of the womb. These tumors usually develop from abnormal cell changes at the entrance to the womb from the vagina (the opening of the cervix). Abnormal cell changes can be detected through screening and then removed. A vaccine against viruses that cause cancer (HPV vaccine) can reduce the risk of cervical cancer. The cervix (neck of the womb) is a strong, muscular tube-like structure. The very bottom end of the cervix sticks out into the vagina a little, at the opening of the cervix. The inside of the cervix is lined with a mucous membrane. Glands in the mucous membrane produce a thick liquid (cervical mucus) that acts as a barrier, preventing germs from entering the womb from the vagina.

UniProtKB/Swiss-Prot: 73 A malignant neoplasm of the cervix, typically originating from a dysplastic or premalignant lesion previously present at the active squamocolumnar junction. The transformation from mild dysplastic to invasive carcinoma generally occurs slowly within several years, although the rate of this process varies widely. Carcinoma in situ is particularly known to precede invasive cervical cancer in most cases. Cervical cancer is strongly associated with infection by oncogenic types of human papillomavirus.

Disease Ontology: 11 A female reproductive organ cancer that is located in the cervix.

Wikipedia: 75 Cervical cancer is a cancer arising from the cervix. It is due to the abnormal growth of cells that have... more...

More information from OMIM: 603956

Related Diseases for Cervical Cancer

Diseases related to Cervical Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1064)
# Related Disease Score Top Affiliating Genes
1 cervix carcinoma 32.8 TP53 MIR214 MIR21 FGFR3 CCND1
2 human papillomavirus infectious disease 32.7 TP53 MIR21 CCND1
3 adenocarcinoma 32.4 TP53 STAT3 MALAT1 H19 FGFR3 CCND1
4 squamous cell carcinoma 32.2 UCA1 TUG1 TP53 STAT3 NEAT1 MALAT1
5 endometrial cancer 31.7 UCA1 TUG1 TP53 STAT3 NEAT1 MIR21
6 retinoblastoma 31.6 TP53 MALAT1 HOTAIR CCND1 CCAT1
7 b-cell lymphoma 31.6 TUG1 TP53 STAT3 PVT1 MALAT1 HOTAIR
8 head and neck cancer 31.4 TP53 STAT3 MIR21 GAS5 CCND1
9 esophageal cancer 31.3 UCA1 TP53 STAT3 PVT1 MIR214 MIR21
10 oropharynx cancer 31.3 TP53 MIR21 CCND1
11 colonic benign neoplasm 31.3 TP53 STAT3 MIR21 CCND1
12 lung cancer susceptibility 3 31.3 TUG1 TP53 STAT3 MIR214 MIR21 MALAT1
13 ovarian cancer 31.2 UCA1 TUG1 TP53 STAT3 SNHG16 PVT1
14 melanoma 31.2 UCA1 TP53 STAT3 PVT1 MIR21 MALAT1
15 lip and oral cavity cancer 31.2 TP53 MIR21 CCND1
16 squamous cell carcinoma, head and neck 31.1 TP53 STAT3 MIR214 MIR21 HOTAIR H19
17 leukemia, chronic lymphocytic 31.1 TP53 STAT3 NEAT1 MIR214 MIR21 CCND1
18 lymphoma 31.1 TP53 STAT3 PVT1 GAS5 CCND1
19 breast cancer 31.0 UCA1 TUG1 TP53 STAT3 SNHG16 PVT1
20 esophagus squamous cell carcinoma 31.0 TUG1 SNHG16 PVT1 MALAT1 HOTAIR GAS5
21 leukemia, acute myeloid 31.0 UCA1 TUG1 TP53 STAT3 MIR21 MALAT1
22 leukemia 31.0 TP53 STAT3 NEAT1 HOTAIR GAS5 CDKN2B-AS1
23 bladder cancer 31.0 UCA1 TUG1 TP53 STAT3 SNHG16 PVT1
24 lymphoma, hodgkin, classic 30.9 TP53 STAT3 PVT1 MIR21
25 hepatocellular carcinoma 30.9 UCA1 TUG1 TP53 STAT3 PVT1 NEAT1
26 colorectal cancer 30.9 UCA1 TUG1 TP53 STAT3 SNHG16 PVT1
27 plasmacytoma 30.9 PVT1 GAS5 CCND1
28 connective tissue disease 30.9 TP53 STAT3 MIR214 MIR21 FGFR3 CCND1
29 ovarian epithelial cancer 30.9 MALAT1 HOTAIR H19 CCAT1
30 kidney cancer 30.9 TP53 PVT1 MIR214 MIR21 MALAT1 HOTAIR
31 lung cancer 30.9 UCA1 TUG1 TP53 STAT3 SNHG16 PVT1
32 acute promyelocytic leukemia 30.8 TP53 STAT3 PVT1 NEAT1 CCND1
33 burkitt lymphoma 30.8 TP53 STAT3 PVT1 NEAT1 MIR21
34 skin squamous cell carcinoma 30.8 TP53 MIR21 HOTAIR CCND1
35 colorectal adenoma 30.8 TP53 MIR21 CCND1
36 bone cancer 30.8 TP53 STAT3 MIR214 MIR21 CCND1
37 rhabdomyosarcoma 30.8 TP53 STAT3 H19 FGFR3 CCND1
38 peripheral t-cell lymphoma 30.8 TP53 STAT3 MIR21 FGFR3
39 teratoma 30.8 TP53 STAT3 H19
40 gastric cancer 30.7 UCA1 TUG1 TP53 STAT3 SNHG16 PVT1
41 small cell cancer of the lung 30.7 TUG1 TP53 MIR21 MALAT1 HOTAIR
42 osteogenic sarcoma 30.7 UCA1 TUG1 TP53 PVT1 NEAT1 MALAT1
43 lymphangioma 30.7 TP53 STAT3 CCND1
44 atypical teratoid rhabdoid tumor 30.7 TP53 HOTAIR CCND1
45 thyroid carcinoma 30.7 UCA1 PVT1 NEAT1 MALAT1 HOTAIR H19
46 nasopharyngeal carcinoma 30.7 TP53 STAT3 PVT1 NEAT1 MIR214 MIR21
47 laryngeal squamous cell carcinoma 30.7 TP53 STAT3 NEAT1 MIR21 MALAT1 HOTAIR
48 brain cancer 30.7 TP53 STAT3 MIR214 MIR21
49 diabetes mellitus 30.7 TUG1 TP53 STAT3 PVT1 MIR21 MALAT1
50 type 2 diabetes mellitus 30.7 TP53 STAT3 PVT1 MIR214 MIR21 GAS5

Comorbidity relations with Cervical Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Hydronephrosis Intestinal Obstruction
Vaginal Cancer

Graphical network of the top 20 diseases related to Cervical Cancer:



Diseases related to Cervical Cancer

Symptoms & Phenotypes for Cervical Cancer

Human phenotypes related to Cervical Cancer:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 neoplasm 30 HP:0002664
2 abnormality of the cervical spine 30 HP:0003319

Clinical features from OMIM®:

603956 (Updated 08-Dec-2022)

UMLS symptoms related to Cervical Cancer:


pelvic pain

Drugs & Therapeutics for Cervical Cancer

PubMed Health treatment related to Cervical Cancer: 63

The most appropriate type of treatment will mainly depend on the size of the tumor and whether the cancer has spread. If the tumor is discovered at a very early stage, a small surgical procedure (conization ) might be enough. If the tumor has already spread to the surrounding tissue , doctors usually recommend having surgery to remove the entire womb (a hysterectomy ). The lymph nodes are removed in a wide area around the womb too. Radiotherapy might also be considered. Radiotherapy is still an option even if the tumor can no longer be removed through surgery. In some patients it can be combined with chemotherapy .

Drugs for Cervical Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 380)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Meperidine Approved Phase 4 57-42-1 4058
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
4
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
5
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
6
Bethanechol Approved Phase 4 674-38-4 2370
7
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
8
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
9
Ferrous fumarate Approved Phase 4 141-01-5
10
Iron Approved Phase 4 7439-89-6 29936
11
Ascorbic acid Approved, Nutraceutical Phase 4 50-81-7 54676860 54670067 5785
12
Rivoceranib Investigational Phase 4 811803-05-1 11315474
13
Epoetin Alfa Phase 4
14 Psychotropic Drugs Phase 4
15 Anesthetics, Intravenous Phase 4
16 Anesthetics, General Phase 4
17 Analgesics, Opioid Phase 4
18 Narcotics Phase 4
19 Monophosphoryl lipid A Phase 4
20 Central Nervous System Stimulants Phase 4
21 Nicotinic Agonists Phase 4
22 Cholinergic Agents Phase 4
23 Vitamins Phase 4
24 Trace Elements Phase 4
25 Micronutrients Phase 4
26 Muscarinic Agonists Phase 4
27 Dopamine Uptake Inhibitors Phase 4
28 Dopamine Agents Phase 4
29 Antidepressive Agents Phase 4
30 Cytochrome P-450 Enzyme Inhibitors Phase 4
31 Fluorodeoxyglucose F18 Phase 4
32
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
33
Hydralazine Approved Phase 3 86-54-4 3637
34
Fluspirilene Approved, Investigational Phase 3 1841-19-6 3396
35
Metronidazole Approved Phase 2, Phase 3 443-48-1, 69198-10-3 4173
36
Cetirizine Approved Phase 3 83881-51-0 2678
37
Famotidine Approved Phase 3 76824-35-6 3325 5702160
38
Histamine Approved, Investigational Phase 3 51-45-6 774
39
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
40
Promethazine Approved, Investigational Phase 3 60-87-7 4927
41
Aluminum sulfate Approved Phase 3 10043-01-3
42
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
43
Heparin, bovine Approved, Investigational, Withdrawn Phase 3 9005-49-6 22833565 9812414 772
44
Reviparin Approved, Investigational Phase 3 9041-08-1
45
Vinblastine Approved Phase 3 865-21-4 241903 13342
46
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
47
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
48
Ondansetron Approved, Withdrawn Phase 3 99614-02-5 4595
49
Granisetron Approved, Investigational Phase 3 109889-09-0 3510 5284566
50
Aprepitant Approved, Investigational Phase 3 170729-80-3 6918365 135413536

Interventional clinical trials:

(show top 50) (show all 1551)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer Unknown status NCT02629510 Phase 4 Tachosil
2 A Prospective, Open, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of PEG-rhG-CSF in Reducing Neutropenia in Patients With Cervical Cancer Unknown status NCT03206684 Phase 4 PEG-rhG-CSF;rhG-CSF
3 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Pilot Study. Unknown status NCT03349463 Phase 4 Fluciclovine F18
4 Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China Unknown status NCT01021904 Phase 4
5 Comparison of Meperidine and Fentanyl on Pain Scale and Quality of Life in Cervical Cancer Patients Receiving Brachytherapy: A Double-blind, Randomized Controlled Trial Completed NCT02684942 Phase 4 Meperidine;Fentanyl
6 HPV Vaccination Impact on Cervical Cancer Screening Program: FASTER-Tlalpan Study in Mexico Completed NCT03105856 Phase 4
7 Effective Surveillance and Impact of HPV Vaccination on Screening for Cervical Cancer in Tuscany Completed NCT02296255 Phase 4
8 Management Of Anemia Under RadioChemotherapy (MARCH): An Open, Randomized Multicenter Study Of The Effect Of NeoRecormon On Treatment Outcome In Patients With Advanced Cervical Cancer Stage IIB -IVA Treated With Primary Simultaneous Radiochemotherapy (Radiotherapy Plus Cisplatin) Completed NCT00046969 Phase 4 cisplatin
9 Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA Completed NCT02910596 Phase 4 bethanechol chloride
10 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
11 Alternate Dosing Schedules Study for HPV Vaccine Completed NCT00862810 Phase 4
12 A Randomized Controlled Trial of Pre-Operative Treatment With Ferrous Fumarate 300 mg Once Daily Versus Placebo in Newly Diagnoses Gynecologic Oncology Patients Who Are Primary Surgical Candidates. Completed NCT01953107 Phase 4
13 Does Intraoperative Application of TachoSil Reduce the Number of Lymphocele After Pelvic Lymphadenectomy? Completed NCT03752606 Phase 4
14 Patient Navigation in the Safety Net:CONNECTeDD Completed NCT00613275 Phase 4
15 Immunogenicity Of A Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, And 18) L1 Virus-Like Particle Vaccine In Male And Female Adolescent Transplant Recipients. Completed NCT01101750 Phase 4
16 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
17 Whether 18F-ALF-NOTA-PRGD2 PET/CT Scan Can Predict the Efficacy and Adverse Events of Apatinib in Patients With Malignancies. Completed NCT03384511 Phase 4 Apatinib
18 Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls Completed NCT01173900 Phase 4
19 A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women Completed NCT01544478 Phase 4
20 Work Package 4: HPV Vaccination of Women in Screening Ages Completed NCT02837926 Phase 4
21 A Study to Assess the Immunogenicity Consistency of Three Consecutive Batches of Commercial-scale of Recombinant Human Papillomavirus(HPV) Bivalent Vaccine (Escherichia Coli) in Healthy Female Subjects Aged 9-14 Years Completed NCT05426148 Phase 4
22 Application of KANG FU PEN (Protective Irrigation Solution Against Rays) in Radical Concurrent Radiotherapy and Chemotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Rectal Injury:a Multicenter, Prospective, Randomized Trail Recruiting NCT04819685 Phase 4 KANG FU PEN
23 Concomitant HPV Vaccination and HPV Screening for Rapid Elimination of HPV Infection and Cervical Cancer in Sweden Recruiting NCT04910802 Phase 4
24 Randomized Controlled Trial to Evaluate the Efficacy of Concurrent Liquid-based Cytology ( LBC) and HPV DNA Testing Versus LBC Alone for the Primary Cervical Cancer Screening Active, not recruiting NCT01895517 Phase 4
25 Randomised Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India Active, not recruiting NCT00923702 Phase 4
26 Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities Terminated NCT00629993 Phase 4
27 A Post-marketing Surveillance (PMS) Study to Monitor the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in 3,000 Healthy Female Filipino Subjects When Administered According to the Prescribing Information From the Age of 10 Years Onwards. Terminated NCT00730847 Phase 4
28 Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer Compared With 18F FDG PET Terminated NCT03423082 Phase 4 18F fluciclovine
29 Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients, A Multicenter, Prospective and Randomized Controlled Trial Unknown status NCT03308591 Phase 3 NACT;Adjuvant chemotherapy
30 Clinical Study on Docetaxel Plus Cisplatin(TP) Regimen Combined With Postoperative Radiotherapy for Stage Ia2- IIb Cervical Cancer Unknown status NCT01999933 Phase 2, Phase 3 cisplatin(DDP) weekly;docetaxel plus cisplatin
31 Improvement of Locally Advanced Cervical Cancer Radiotherapy Efficacy by Use of Volumetric Arc Therapy, Individualized Polyradiosensitization and Interstitial Brachytherapy Unknown status NCT02957266 Phase 3 Cisplatin;Gemcitabine
32 A Phase III Randomised Trial Investigating the Benefits of the Addition of Modulated Electro-hyperthermia to Chemo-radiation for Cervical Cancer in HIV Positive and Negative Women in South Africa Unknown status NCT03332069 Phase 3 Cisplatin
33 A Trial of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer(CSEM005) Unknown status NCT02629718 Phase 3 NACT (Paclitaxel + Cisplatin or carboplatin)
34 A Phase III Randomized Trial Between 5 Day 3 Weekly and Weekly Cisplatin Based Chemotherapy for Patients With Locally Advanced Cervical Cancer Unknown status NCT00548821 Phase 3 Cisplatin
35 Multicenter Study on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy With Cisplatin and Docetaxel Combined With Radiotherapy for Local Advanced Cervical Cancer Unknown status NCT02703961 Phase 3 concurrent chemotherapy with cisplatin;concurrent chemotherapy with docetaxel;adjuvant chemotherapy with cisplatin and docetaxel
36 Neoadjuvant Chemotherapy and Radical Surgery Versus Concurrent Chemoirradiation in FIGO Stage IIB Cervical Cancer Unknown status NCT02595554 Phase 3 Paclitaxel;Cisplatin
37 Randomized Controlled Trial Comparing Concurrent Chemoradiation Versus Concurrent Chemoradiation Followed by Adjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients Unknown status NCT02036164 Phase 3 Cisplatin;Paclitaxel;Carboplatin
38 a Prospective Random Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer Unknown status NCT04138992 Phase 2, Phase 3 bevacizumab;DDP;Docetaxel
39 Phase III Trial for Primary Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in PET/CT Defined Poor-Prognostic Cervical Cancer Patients Unknown status NCT00842660 Phase 3 Gemzar (gemcitabine)
40 Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Recurrent and Metastatic Cervical Cancer. Unknown status NCT00532818 Phase 3 Hydralazine and magnesium valproate;Placebo
41 Phase III Randomized Trial of Comparing CCRT vs. RT Alone for Cervical Cancer Patients Primarily Treated by Radiotherapy and With Clinically Defined Good-prognosis Unknown status NCT00846508 Phase 3 Cisplatin
42 Individualized Precise Radiotherapy With the Guidance of Radiosensitivity: A Study on the Clinical Management Model of Locally Advanced Cervical Cancer Unknown status NCT03163979 Phase 2, Phase 3
43 A Study of QL1604 Plus Chemotherapy Versus Chemotherapy Plus Placebo With Stage ⅣB, Recurrent, or Metastatic Cervical Cancer Unknown status NCT04864782 Phase 2, Phase 3 QL1604;Paclitaxel injection;Cisplatin/Carboplatin
44 Randomized Phase III Study Of Neoadjuvant Chemotherapy Followed By Surgery Vs. Concomitant Radiotherapy And Chemotherapy In FIGO Ib2, IIa>4 cm or IIb Cervical Cancer Unknown status NCT00039338 Phase 3 cisplatin
45 Phase III Clinical Trial: "Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer Unknown status NCT02446652 Phase 3 Hydralazine/Magnesium;Placebo;Carboplatin;Paclitaxel
46 A Phase III Randomized Trial of FDG-PET in the Management of Advanced Cervical Cancer With Enlarged Pelvic Lymph Node on MRI Image Unknown status NCT00146458 Phase 3
47 Randomized Controlled Trial of Vaginal Self Sampling for Human Papillomavirus to Increase Cervical Cancer Screening Participation Unknown status NCT01095198 Phase 2, Phase 3
48 Phase III Randomized Study of Concurrent Paclitaxel/Cisplatin Chemotherapy and Radiotherapy With or Without Consolidation Chemotherapy in High-Risk Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy Unknown status NCT01755845 Phase 3 paclitaxel;cisplatin
49 A Prospective, Randomized Phase III Study to Compare the Effects of Paclitaxel and Topotecan to Those of Cisplatin and Topotecan for Treatment of Patients With Recurrent and Persistent Cervical Cancer Unknown status NCT01405235 Phase 3 Paclitaxel;Cisplatin/Paclitaxel
50 Phase III Randomized Trial of Comparing Chemoradiotherapy vs. Radiotherapy Alone in Lymph Node Negative Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy Unknown status NCT01756170 Phase 3 paclitaxel;cisplatin

Search NIH Clinical Center for Cervical Cancer

Cochrane evidence based reviews: uterine cervical neoplasms

Genetic Tests for Cervical Cancer

Genetic tests related to Cervical Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of Uterine Cervix 28

Anatomical Context for Cervical Cancer

Organs/tissues related to Cervical Cancer:

FMA: Cervix
MalaCards : Cervix, Uterus, Lymph Node, Breast, T Cells, Colon, Prostate

Publications for Cervical Cancer

Articles related to Cervical Cancer:

(show top 50) (show all 35506)
# Title Authors PMID Year
1
Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. 53 62 57 5
1349102 1992
2
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. 57 5
10471491 1999
3
Somatic LKB1 mutations promote cervical cancer progression. 53 62 57
19340305 2009
4
Integrated genomic and molecular characterization of cervical cancer. 62 57
28112728 2017
5
PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. 62 57
23266353 2013
6
Neoadjuvant chemotherapy for patients with international federation of gynecology and obstetrics stages IB3 and IIA2 cervical cancer: a multicenter prospective trial. 62 41
36471257 2022
7
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
8
Landscape of genomic alterations in cervical carcinomas. 57
24390348 2014
9
MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. 62 46
19859982 2009
10
Patterns of known and novel small RNAs in human cervical cancer. 62 46
17616659 2007
11
Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. 57
17360030 2007
12
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. 5
15772091 2005
13
Genetic link to cervical tumours. 57
10403244 1999
14
Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. 5
8589699 1995
15
Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. 57
8041728 1994
16
Mutational hotspot in the p53 gene in human hepatocellular carcinomas. 5
1849234 1991
17
A genetic model for colorectal tumorigenesis. 57
2188735 1990
18
Effect of Patient Characteristics on Uptake of Screening Using a Mailed Human Papillomavirus Self-sampling Kit: A Secondary Analysis of a Randomized Clinical Trial. 41
36449291 2022
19
Impact of HPV vaccination on HPV infection and cervical related disease burden in real-world settings (HPV-RWS): protocol of a prospective cohort. 41
36401179 2022
20
HIF-1 and NDRG2 contribute to hypoxia-induced radioresistance of cervical cancer Hela cells. 53 62
20206160 2010
21
Low expression of human histocompatibility soluble leukocyte antigen-G (HLA-G5) in invasive cervical cancer with and without metastasis, associated with papilloma virus (HPV). 53 62
19786613 2010
22
DeltaNp63alpha repression of the Notch1 gene supports the proliferative capacity of normal human keratinocytes and cervical cancer cells. 53 62
20442293 2010
23
ARL6IP1 mediates cisplatin-induced apoptosis in CaSki cervical cancer cells. 53 62
20372863 2010
24
Analysis of expression and structure of the TSG101 gene in cervical cancer cells. 53 62
20372822 2010
25
Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6. 53 62
20167600 2010
26
Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. 53 62
20429915 2010
27
Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion. 53 62
20213048 2010
28
Homozygous deletion of the STK11/LKB1 locus and the generation of novel fusion transcripts in cervical cancer cells. 53 62
20193846 2010
29
Human papillomavirus type 16 E5 protein inhibits hydrogen-peroxide-induced apoptosis by stimulating ubiquitin-proteasome-mediated degradation of Bax in human cervical cancer cells. 53 62
20015862 2010
30
TP53, MDM2, NQO1, and susceptibility to cervical cancer. 53 62
20200430 2010
31
Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. 53 62
19913895 2010
32
Fibronectin-integrin mediated signaling in human cervical cancer cells (SiHa). 53 62
19816757 2010
33
Oncosuppressor proteins of fragile sites are reduced in cervical cancer. 53 62
19700237 2010
34
Anti-angiogenesis agents in metastatic or recurrent cervical cancer. 53 62
19861227 2010
35
Novel missense mutation in FHIT gene: interpreting the effect in HPV-mediated cervical cancer in Indian women. 53 62
19730990 2010
36
[Exploring the issue of cervical cancer prevention and control in women living with HIV/AIDS]. 53 62
20127625 2010
37
Gene promoter methylation patterns throughout the process of cervical carcinogenesis. 53 62
20208141 2010
38
Use of tissue microarray to facilitate oncology research. 53 62
20217582 2010
39
Kinetics of transport and phosphorylation of glucose in cancer cells. 53 62
19681047 2009
40
The effect of cyclooxygenase-2 expression on tumor volume response in patients treated with radiotherapy for uterine cervical cancer. 53 62
19949677 2009
41
[Mechanism of anti-tumor effect of HIF-1alpha silencing on cervical cancer in nude mice]. 53 62
20137345 2009
42
Tristetraprolin: a weapon against HPV-induced cervical cancer? 53 62
20157555 2009
43
Cooperation of decay-accelerating factor and membrane cofactor protein in regulating survival of human cervical cancer cells. 53 62
19878546 2009
44
Folate status and aberrant DNA methylation are associated with HPV infection and cervical pathogenesis. 53 62
19755648 2009
45
MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. 46
19682430 2009
46
Reactive oxygen species-dependent activation of Bax and poly(ADP-ribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells. 53 62
19574249 2009
47
The mRNA decay factor tristetraprolin (TTP) induces senescence in human papillomavirus-transformed cervical cancer cells by targeting E6-AP ubiquitin ligase. 53 62
20157568 2009
48
Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86. 53 62
19672258 2009
49
Immunohistochemical expression of ubiquitin and telomerase in cervical cancer. 53 62
19680685 2009
50
The nonsynonymous single-nucleotide polymorphisms in codon 31 of p21 gene and the susceptibility to cervical cancer in Chinese women. 53 62
19820361 2009

Variations for Cervical Cancer

ClinVar genetic disease variations for Cervical Cancer:

5 (show top 50) (show all 144)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TP53 NM_000546.6(TP53):c.747G>T (p.Arg249Ser) SNV Pathogenic
12352 rs28934571 GRCh37: 17:7577534-7577534
GRCh38: 17:7674216-7674216
2 FGFR3 NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) SNV Pathogenic
Pathogenic
16339 rs121913483 GRCh37: 4:1803568-1803568
GRCh38: 4:1801841-1801841
3 FGFR3 NM_000142.5(FGFR3):c.742C>T (p.Arg248Cys) SNV Pathogenic
Pathogenic
16332 rs121913482 GRCh37: 4:1803564-1803564
GRCh38: 4:1801837-1801837
4 FGFR3 NM_000142.5(FGFR3):c.749C>G (p.Pro250Arg) SNV Pathogenic
16340 rs4647924 GRCh37: 4:1803571-1803571
GRCh38: 4:1801844-1801844
5 FGFR3 NM_000142.5(FGFR3):c.1138G>A (p.Gly380Arg) SNV Pathogenic
16327 rs28931614 GRCh37: 4:1806119-1806119
GRCh38: 4:1804392-1804392
6 FGFR3 NM_000142.5(FGFR3):c.1620C>G (p.Asn540Lys) SNV Pathogenic
16338 rs28933068 GRCh37: 4:1807371-1807371
GRCh38: 4:1805644-1805644
7 FGFR3 NM_000142.5(FGFR3):c.1949A>C (p.Lys650Thr) SNV Pathogenic
65855 rs121913105 GRCh37: 4:1807890-1807890
GRCh38: 4:1806163-1806163
8 PIK3CA NM_006218.4(PIK3CA):c.1031T>C (p.Val344Ala) SNV Likely Pathogenic
376499 rs1057519941 GRCh37: 3:178921549-178921549
GRCh38: 3:179203761-179203761
9 PIK3CA NM_006218.4(PIK3CA):c.316G>C (p.Gly106Arg) SNV Likely Pathogenic
376480 rs1057519931 GRCh37: 3:178916929-178916929
GRCh38: 3:179199141-179199141
10 FBXW7 NM_001349798.2(FBXW7):c.1973G>A (p.Arg658Gln) SNV Likely Pathogenic
376427 rs759610249 GRCh37: 4:153244184-153244184
GRCh38: 4:152323032-152323032
11 TP53 NM_000546.6(TP53):c.394A>C (p.Lys132Gln) SNV Likely Pathogenic
376628 rs747342068 GRCh37: 17:7578536-7578536
GRCh38: 17:7675218-7675218
12 TP53 NM_000546.6(TP53):c.395A>C (p.Lys132Thr) SNV Likely Pathogenic
376627 rs1057519996 GRCh37: 17:7578535-7578535
GRCh38: 17:7675217-7675217
13 SMAD4 NM_005359.6(SMAD4):c.1082G>C (p.Arg361Pro) SNV Likely Pathogenic
376541 rs377767347 GRCh37: 18:48591919-48591919
GRCh38: 18:51065549-51065549
14 TP53 NM_000546.6(TP53):c.581T>C (p.Leu194Pro) SNV Likely Pathogenic
376635 rs1057519998 GRCh37: 17:7578268-7578268
GRCh38: 17:7674950-7674950
15 TP53 NM_000546.6(TP53):c.839G>T (p.Arg280Ile) SNV Likely Pathogenic
161517 rs121912660 GRCh37: 17:7577099-7577099
GRCh38: 17:7673781-7673781
16 TP53 NM_000546.6(TP53):c.395A>T (p.Lys132Met) SNV Likely Pathogenic
376629 rs1057519996 GRCh37: 17:7578535-7578535
GRCh38: 17:7675217-7675217
17 PTEN NM_000314.8(PTEN):c.388C>G (p.Arg130Gly) SNV Likely Pathogenic
375958 rs121909224 GRCh37: 10:89692904-89692904
GRCh38: 10:87933147-87933147
18 HRAS, LRRC56 NM_005343.4(HRAS):c.37G>C (p.Gly13Arg) SNV Likely Pathogenic
35554 rs104894228 GRCh37: 11:534286-534286
GRCh38: 11:534286-534286
19 TP53 NM_000546.6(TP53):c.396G>C (p.Lys132Asn) SNV Likely Pathogenic
376624 rs866775781 GRCh37: 17:7578534-7578534
GRCh38: 17:7675216-7675216
20 CTNNB1 NM_001904.4(CTNNB1):c.94G>C (p.Asp32His) SNV Likely Pathogenic
376054 rs28931588 GRCh37: 3:41266097-41266097
GRCh38: 3:41224606-41224606
21 MAPK1 NM_002745.5(MAPK1):c.964G>A (p.Glu322Lys) SNV Likely Pathogenic
376450 rs1057519911 GRCh37: 22:22127164-22127164
GRCh38: 22:21772875-21772875
22 CTNNB1 NM_001904.4(CTNNB1):c.110C>T (p.Ser37Phe) SNV Likely Pathogenic
17586 rs121913403 GRCh37: 3:41266113-41266113
GRCh38: 3:41224622-41224622
23 CTNNB1 NM_001904.4(CTNNB1):c.110C>A (p.Ser37Tyr) SNV Likely Pathogenic
375894 rs121913403 GRCh37: 3:41266113-41266113
GRCh38: 3:41224622-41224622
24 CTNNB1 NM_001904.4(CTNNB1):c.110C>G (p.Ser37Cys) SNV Likely Pathogenic
17579 rs121913403 GRCh37: 3:41266113-41266113
GRCh38: 3:41224622-41224622
25 CTNNB1 NM_001904.4(CTNNB1):c.94G>A (p.Asp32Asn) SNV Likely Pathogenic
376228 rs28931588 GRCh37: 3:41266097-41266097
GRCh38: 3:41224606-41224606
26 PIK3CA NM_006218.4(PIK3CA):c.241G>A (p.Glu81Lys) SNV Likely Pathogenic
376478 rs1057519929 GRCh37: 3:178916854-178916854
GRCh38: 3:179199066-179199066
27 HRAS, LRRC56 NM_005343.4(HRAS):c.34G>T (p.Gly12Cys) SNV Likely Pathogenic
12613 rs104894229 GRCh37: 11:534289-534289
GRCh38: 11:534289-534289
28 HRAS, LRRC56 NM_005343.4(HRAS):c.35G>C (p.Gly12Ala) SNV Likely Pathogenic
12603 rs104894230 GRCh37: 11:534288-534288
GRCh38: 11:534288-534288
29 HRAS, LRRC56 NM_005343.4(HRAS):c.37G>T (p.Gly13Cys) SNV Likely Pathogenic
12606 rs104894228 GRCh37: 11:534286-534286
GRCh38: 11:534286-534286
30 TP53 NM_000546.6(TP53):c.581T>G (p.Leu194Arg) SNV Likely Pathogenic
376633 rs1057519998 GRCh37: 17:7578268-7578268
GRCh38: 17:7674950-7674950
31 SMAD4 NM_005359.6(SMAD4):c.1082G>A (p.Arg361His) SNV Likely Pathogenic
24832 rs377767347 GRCh37: 18:48591919-48591919
GRCh38: 18:51065549-51065549
32 PIK3CA NM_006218.4(PIK3CA):c.112C>T (p.Arg38Cys) SNV Likely Pathogenic
376493 rs749415085 GRCh37: 3:178916725-178916725
GRCh38: 3:179198937-179198937
33 TP53 NM_000546.6(TP53):c.712T>C (p.Cys238Arg) SNV Likely Pathogenic
376576 rs1057519981 GRCh37: 17:7577569-7577569
GRCh38: 17:7674251-7674251
34 TP53 NM_000546.6(TP53):c.580C>T (p.Leu194Phe) SNV Likely Pathogenic
127817 rs587780071 GRCh37: 17:7578269-7578269
GRCh38: 17:7674951-7674951
35 TP53 NM_000546.6(TP53):c.712T>G (p.Cys238Gly) SNV Likely Pathogenic
376577 rs1057519981 GRCh37: 17:7577569-7577569
GRCh38: 17:7674251-7674251
36 TP53 NM_000546.6(TP53):c.839G>C (p.Arg280Thr) SNV Likely Pathogenic
12368 rs121912660 GRCh37: 17:7577099-7577099
GRCh38: 17:7673781-7673781
37 CREBBP NM_004380.3(CREBBP):c.4336C>T (p.Arg1446Cys) SNV Likely Pathogenic
95047 rs398124146 GRCh37: 16:3788618-3788618
GRCh38: 16:3738617-3738617
38 SMAD4 NM_005359.6(SMAD4):c.1081C>G (p.Arg361Gly) SNV Likely Pathogenic
24830 rs80338963 GRCh37: 18:48591918-48591918
GRCh38: 18:51065548-51065548
39 TP53 NM_000546.6(TP53):c.839G>A (p.Arg280Lys) SNV Likely Pathogenic
376657 rs121912660 GRCh37: 17:7577099-7577099
GRCh38: 17:7673781-7673781
40 PTEN NM_000314.8(PTEN):c.389G>C (p.Arg130Pro) SNV Likely Pathogenic
142018 rs121909229 GRCh37: 10:89692905-89692905
GRCh38: 10:87933148-87933148
41 TP53 NM_000546.6(TP53):c.395A>G (p.Lys132Arg) SNV Likely Pathogenic
376625 rs1057519996 GRCh37: 17:7578535-7578535
GRCh38: 17:7675217-7675217
42 PTEN NM_000314.8(PTEN):c.389G>A (p.Arg130Gln) SNV Likely Pathogenic
7829 rs121909229 GRCh37: 10:89692905-89692905
GRCh38: 10:87933148-87933148
43 PIK3CA NM_006218.4(PIK3CA):c.1624G>A (p.Glu542Lys) SNV Likely Pathogenic
31944 rs121913273 GRCh37: 3:178936082-178936082
GRCh38: 3:179218294-179218294
44 TP53 NM_000546.6(TP53):c.581T>A (p.Leu194His) SNV Likely Pathogenic
376634 rs1057519998 GRCh37: 17:7578268-7578268
GRCh38: 17:7674950-7674950
45 PTEN NM_000314.8(PTEN):c.389G>T (p.Arg130Leu) SNV Likely Pathogenic
376509 rs121909229 GRCh37: 10:89692905-89692905
GRCh38: 10:87933148-87933148
46 GNAS NM_000516.7(GNAS):c.601C>T (p.Arg201Cys) SNV Likely Pathogenic
15933 rs11554273 GRCh37: 20:57484420-57484420
GRCh38: 20:58909365-58909365
47 PTEN NM_000314.8(PTEN):c.698G>A (p.Arg233Gln) SNV Likely Pathogenic
376510 rs770025422 GRCh37: 10:89717673-89717673
GRCh38: 10:87957916-87957916
48 TP53 NM_000546.6(TP53):c.394A>G (p.Lys132Glu) SNV Likely Pathogenic
376626 rs747342068 GRCh37: 17:7578536-7578536
GRCh38: 17:7675218-7675218
49 TP53 NM_000546.6(TP53):c.713G>T (p.Cys238Phe) SNV Likely Pathogenic
376574 rs730882005 GRCh37: 17:7577568-7577568
GRCh38: 17:7674250-7674250
50 GNAS NM_000516.7(GNAS):c.602G>A (p.Arg201His) SNV Likely Pathogenic
15934 rs121913495 GRCh37: 20:57484421-57484421
GRCh38: 20:58909366-58909366

UniProtKB/Swiss-Prot genetic disease variations for Cervical Cancer:

73
# Symbol AA change Variation ID SNP ID
1 FGFR3 p.Ser249Cys VAR_004149 rs121913483

Copy number variations for Cervical Cancer from CNVD:

6 (show top 50) (show all 142)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13747 1 1 27800000 Gain EPHB2 Cervical cancer
2 16425 1 124300000 247249719 Arm Cervical cancer
3 30310 1 241700000 247249719 Gain Cervical cancer
4 31746 1 30500000 163800000 Gain AIM2 Cervical cancer
5 32175 1 34400000 39600000 Gain CDCA8 Cervical cancer
6 47124 10 89600000 98000000 Loss PTEN Cervical cancer
7 48645 11 101600000 102400000 Amplification MMP1 Cervical cancer
8 48646 11 101600000 102400000 Amplification MMP13 Cervical cancer
9 51761 11 130300000 134452384 Loss Cervical cancer
10 51791 11 130800000 135006516 Loss NTM Cervical cancer
11 51792 11 130800000 135006516 Loss OPCML Cervical cancer
12 55435 11 52900000 134452384 Loss Cervical cancer
13 57095 11 63100000 130300000 Loss FGF3 Cervical cancer
14 57096 11 63100000 130300000 Loss MEN1 Cervical cancer
15 57097 6 99389300 99393387 Loss POU3F2 Cervical cancer
16 57098 11 63100000 130300000 Loss TRIM29 Cervical cancer
17 59362 11 74700000 85300000 Gain Cervical cancer
18 77051 13 39500000 52200000 Loss RB1 Cervical cancer
19 81044 14 100400000 106368585 Gain AKT1 Cervical cancer
20 97280 16 1 40700000 Loss Cervical cancer
21 106741 17 1 11200000 Loss TP53 Cervical cancer
22 108734 17 22200000 28800000 Loss CCL2 Cervical cancer
23 109725 17 28500000 29700000 Amplification Cervical cancer
24 109738 17 28800000 35400000 Amplification ERBB2 Cervical cancer
25 111034 17 34900000 35300000 Amplification Cervical cancer
26 111283 17 35400000 54900000 Amplification ABCC3 Cervical cancer
27 112092 17 37856253 37884915 Amplification ERBB2 Cervical cancer
28 112304 17 38544772 38574202 Amplification TOP2A Cervical cancer
29 117589 17 72900000 78774742 Gain Cervical cancer
30 124103 19 1 30200000 Gain Cervical cancer
31 124104 19 1 30200000 Loss Cervical cancer
32 124177 19 1 6900000 Gain SMARCA4 Cervical cancer
33 124219 19 1 6900000 Gain Cervical cancer
34 124597 19 1156797 1179434 Deletion STK11 Cervical Cancer
35 124598 19 1156797 1179434 Deletion STK11 Cervical cancer
36 130163 19 47800000 57600000 Gain LIG1 Cervical cancer
37 134165 19 9500000 14500000 Gain Cervical cancer
38 140388 2 197100000 242951149 Loss CASP10 Cervical cancer
39 140389 2 197100000 242951149 Loss CFLAR Cervical cancer
40 140390 2 197100000 242951149 Loss PPP1R7 Cervical cancer
41 151917 20 27100000 28400000 Amplification AHCY Cervical cancer
42 151918 20 27100000 28400000 Amplification ASXL1 Cervical cancer
43 151919 20 27100000 28400000 Amplification MRGBP Cervical cancer
44 151920 20 27100000 28400000 Amplification E2F1 Cervical cancer
45 151921 20 27100000 28400000 Amplification GSS Cervical cancer
46 151922 20 27100000 28400000 Amplification KIF3B Cervical cancer
47 151923 20 27100000 28400000 Amplification POFUT1 Cervical cancer
48 151924 20 27100000 28400000 Amplification TPX2 Cervical cancer
49 153446 20 37100000 41100000 Gain ANIB1 Cervical cancer
50 153736 20 41100000 49200000 Amplification ADNP Cervical cancer

Expression for Cervical Cancer

LifeMap Discovery
Genes differentially expressed in tissues of Cervical Cancer patients vs. healthy controls: 35 (show top 50) (show all 70)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 KRT1 keratin 1 Uterus - 5.47 0.000
2 KRTDAP keratinocyte differentiation associated protein Uterus - 4.96 0.000
3 CTHRC1 collagen triple helix repeat containing 1 Uterus + 4.65 0.000
4 TMPRSS11B transmembrane serine protease 11B Uterus - 4.58 0.000
5 CDKN2A cyclin dependent kinase inhibitor 2A Uterus + 4.45 0.000
6 CMPK2 cytidine/uridine monophosphate kinase 2 Uterus + 4.32 0.000
7 CRNN cornulin Uterus - 4.25 0.000
8 MAL mal, T cell differentiation protein Uterus - 4.21 0.000
9 DSG1 desmoglein 1 Uterus - 4.17 0.000
10 ECT2 epithelial cell transforming 2 Uterus + 4.10 0.000
11 SYCP2 synaptonemal complex protein 2 Uterus + 3.95 0.000
12 HS6ST2 heparan sulfate 6-O-sulfotransferase 2 Uterus + 3.94 0.000
13 KIF14 kinesin family member 14 Uterus + 3.88 0.000
14 IFI44 interferon induced protein 44 Uterus + 3.88 0.000
15 MMP1 matrix metallopeptidase 1 Uterus + 3.83 0.001
16 GREB1 growth regulating estrogen receptor binding 1 Uterus - 3.78 0.000
17 KRT17 keratin 17 Uterus + 3.71 0.000
18 SPINK7 serine peptidase inhibitor Kazal type 7 Uterus - 3.70 0.000
19 NUF2 NUF2 component of NDC80 kinetochore complex Uterus + 3.70 0.000
20 NCEH1 neutral cholesterol ester hydrolase 1 Uterus + 3.64 0.000
21 PLSCR1 phospholipid scramblase 1 Uterus + 3.63 0.000
22 E2F7 E2F transcription factor 7 Uterus + 3.62 0.000
23 SLF1 SMC5-SMC6 complex localization factor 1 Uterus + 3.61 0.000
24 INHBA inhibin subunit beta A Uterus + 3.59 0.001
25 DAPL1 death associated protein like 1 Uterus - 3.57 0.000
26 KRT4 keratin 4 Uterus - 3.53 0.000
27 SMC4 structural maintenance of chromosomes 4 Uterus + 3.50 0.000
28 CEP55 centrosomal protein 55 Uterus + 3.49 0.000
29 LOX lysyl oxidase Uterus + 3.48 0.000
30 ANLN anillin, actin binding protein Uterus + 3.48 0.000
31 ITGB1 integrin subunit beta 1 Uterus + 3.46 0.000
32 CRISP3 cysteine rich secretory protein 3 Uterus - 3.46 0.001
33 HELLS helicase, lymphoid specific Uterus + 3.44 0.000
34 KRT19 keratin 19 Uterus + 3.44 0.002
35 SPP1 secreted phosphoprotein 1 Uterus + 3.43 0.000
36 CNFN cornifelin Uterus - 3.42 0.000
37 EPCAM epithelial cell adhesion molecule Uterus + 3.39 0.000
38 NDC80 NDC80 kinetochore complex component Uterus + 3.35 0.000
39 SCD stearoyl-CoA desaturase Uterus + 3.31 0.000
40 CRCT1 cysteine rich C-terminal 1 Uterus - 3.31 0.002
41 KRT13 keratin 13 Uterus - 3.30 0.010
42 CDK1 cyclin dependent kinase 1 Uterus + 3.30 0.000
43 DDIT4 DNA damage inducible transcript 4 Uterus + 3.29 0.000
44 ARMT1 acidic residue methyltransferase 1 Uterus + 3.29 0.000
45 ALOX12 arachidonate 12-lipoxygenase, 12S type Uterus - 3.28 0.000
46 ATAD2 ATPase family AAA domain containing 2 Uterus + 3.27 0.000
47 ZIC2 Zic family member 2 Uterus + 3.26 0.000
48 ARHGAP21 Rho GTPase activating protein 21 Uterus + 3.24 0.000
49 LYN LYN proto-oncogene, Src family tyrosine kinase Uterus + 3.24 0.000
50 PPIB peptidylprolyl isomerase B Uterus + 3.23 0.000
Search GEO for disease gene expression data for Cervical Cancer.

Pathways for Cervical Cancer

GO Terms for Cervical Cancer

Biological processes related to Cervical Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.73 TP53 STAT3 MIR214 MIR21 CDKN2B-AS1
2 response to leptin GO:0044321 9.67 STAT3 CCND1
3 negative regulation of miRNA-mediated gene silencing GO:0060965 9.5 PVT1 NEAT1
4 positive regulation of metalloendopeptidase activity GO:1904685 9.33 STAT3 MIR21
5 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.26 STAT3 MIR21 H19
6 negative regulation of superoxide dismutase activity GO:1901670 8.62 MIR21 H19

Molecular functions related to Cervical Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 miRNA binding GO:0035198 8.92 PVT1 NEAT1 GAS5

Sources for Cervical Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....